만성 폐쇄성 폐질환(COPD) 치료 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
상품코드:1672817
리서치사:Coherent Market Insights
발행일:2025년 02월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 만성 폐쇄성 폐질환(COPD) 치료 시장은 2025년에는 203억 5,000만 달러로 추정되며, 2032년에는 304억 1,000만 달러에 달할 것으로 예측되며, 2025-2032년 연간 평균 성장률(CAGR)은 5.9%로 성장할 전망입니다.
리포트 범위
리포트 상세
기준연도
2024
2025년 시장 규모
203억 5,000만 달러
실적 데이터
2020-2024년
예측 기간
2025-2032년
예측 기간 : 2025-2032년 CAGR :
5.90%
2032년 가치 예측
304억 1,000만 달러
도표. 만성 폐쇄성 폐질환(COPD) 치료 시장 점유율(%), 2025년 지역별
만성폐쇄성폐질환(COPD)은 기류가 막히고 호흡 관련 문제를 일으키는 폐질환을 말합니다. COPD의 주요 원인으로는 담배 흡연, 먼지, 연기 등 작업장에서의 폐 자극 물질 노출, 대기 오염 등이 있으며, COPD의 주요 증상으로는 호흡곤란, 기침, 점액(가래) 분비, 천명음 등이 있습니다. 이 저하되어 호흡곤란이 발생합니다.
시장 역학:
세계 만성폐쇄성폐질환(COPD) 치료제 시장의 성장은 높은 흡연율, 전 세계 대기오염 수준 증가, 노인 인구 증가, 질병 및 치료 옵션에 대한 인식 증가 등의 요인에 기인합니다. 그러나 COPD 및 폐암과 같은 관련 합병증에 대한 완전한 치료법이 없습니다는 점이 시장 성장에 걸림돌이 될 수 있습니다. 제약회사들은 COPD에 대한 새로운 생물학적 제제의 연구개발에 투자하고 있으며, 이는 시장 성장에 유리한 기회를 제공할 수 있습니다. 기업들은 COPD의 증상과 악화를 효과적으로 치료하기 위해 에피네프린 자동주사기, 기관지 확장제, 흡입용 코르티코스테로이드, 병용요법 등을 개발하고 있습니다.
본 조사의 주요 특징
세계의 만성폐쇄성폐질환(COPD) 치료제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(미화억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
세계 만성폐쇄성폐질환(COPD) 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 주요 성과, 전략 등을 기준으로 정리하여 수록하였습니다.
주요 기업에는 AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc, CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck &Co., Inc, Grifols, S.A., Almirall, S.A., Genentech, Inc. 등이 있습니다.
이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
세계 만성폐쇄성폐질환(COPD) 치료제 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 만성폐쇄성폐질환(COPD) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
제1장 조사의 목적과 전제조건
조사 목적
전제조건
약어
제2장 시장 전망
리포트 설명
시장의 정의와 범위
개요
Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
시장 역학
촉진요인
억제요인
기회
영향 분석
역학
시장 동향
주요 발전
규제 시나리오
제조업체 매출
인수와 제휴 시나리오
제품 발매/승인
자금조달과 투자
PEST 분석
Porter의 산업 분석
제4장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
전체적인 영향
정부 구상
시장에 대한 COVID-19의 영향
제5장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 약제 클래스별, 2020-2032년(10억 달러)
기관지 확장약
포스포디에스테라제 4 저해제
코르티코스테로이드
기타
제6장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 투여 경로별, 2020-2032년, (10억 달러)
경구
흡입
제7장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 유통 채널별, 2020-2032년, (10억 달러)
병원 약국
소매 약국
온라인 약국
제8장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 지역별, 2020-2032년, (10억 달러)
북미
라틴아메리카
유럽
아시아태평양
중동
아프리카
제9장 경쟁 구도
기업 개요
AstraZeneca
Orion Corporation
Mylan NV
Teva Pharmaceutical Industries Ltd.
GSK plc
Novartis AG
Sunovion Pharmaceuticals, Inc.
CHIESI Farmaceutici SpA
Alembic Pharmaceuticals Ltd
Verona Pharmaceuticals
Theravance Biopharma
F. Hoffmann-La Roche Ltd
Sanofi
Boehringer Ingelheim International GmbH
Merck &Co., Inc
Grifols, SA
Almirall, SA
Genentech, Inc
제10장 애널리스트의 권장사항
제11장 참고 문헌과 조사 방법
참고 문헌
조사 방법
KSA
영문 목차
영문목차
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 20.35 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
5.90%
2032 Value Projection:
USD 30.41 Bn
Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025
Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.
Market Dynamics:
Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.
Key Features of the Study:
This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market
Detailed Segmentation-
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Corticosteroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles:
AstraZeneca
Orion Corporation
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
GSK plc
Novartis AG
Sunovion Pharmaceuticals, Inc.
CHIESI Farmaceutici SpA
Alembic Pharmaceuticals Ltd
Verona Pharmaceuticals
Theravance Biopharma
Hoffmann-La Roche Ltd
Sanofi
Boehringer Ingelheim International GmbH
Merck & Co., Inc
Grifols, S.A.
Almirall, S.A
Genentech, Inc
Table of Contents (TOC)
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Drug Class
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Opportunities
Impact Analysis
Epidemiology
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis
4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
Overall Impact
Government Initiatives
COVID-19 Impact on the Market
5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)
Overview
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Bronchodilators
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Beta 2-Agonists
Anticholinergics
Theophyllines
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phosphodiesterase Type 4 Inhibitors
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Corticosteroids
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)
Overview
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Inhalation
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)
Overview
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)
Introduction
Market Share Analysis, By Region, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Region, 2021-2032
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
